Chapurlat, Roland <br/><br/>
Effects and management of denosumab discontinuation.  [electronic resource] 

 -  Joint bone spine  10 2018 
 - 515-517 p.  digital 
<br/><br/> Publication Type: Editorial; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1778-7254 
<br/><br/><label>Standard No.: </label>10.1016/j.jbspin.2017.12.013  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Bone Density Conservation Agents--adverse effects<br/>Denosumab--adverse effects<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Osteoporosis, Postmenopausal--diagnosis<br/>Osteoporotic Fractures--prevention & control<br/>Patient Safety<br/>Prognosis<br/>Retreatment<br/>Time Factors<br/>Withholding Treatment